Company
MacroGenics
MacroGenics has 24 drugs tracked on RxWires: 2 in Phase 3, 1 in Phase 2/3, 3 in Phase 2, 4 in Phase 1/2, 14 in Phase 1.
Pipeline
| Drug | Phase | Indication |
|---|---|---|
| Margetuximab | Phase 3 | HER-2 Positive Breast Cancer |
| Teplizumab Herold Regimen | Phase 3 | Type 1 Diabetes Mellitus |
| enoblituzumab | Phase 2/3 | Head and Neck Cancer |
| Lorigerlimab | Phase 2 | Metastatic Cancer |
| Regorafenib (CT) | Phase 2 | Colorectal Cancer |
| vobramitamab duocarmazine 2.0 mg (Arm A) | Phase 2 | Castration-Resistant Prostatic Cancer |
| Margetuximab 10 mg/kg | Phase 1/2 | Gastric Cancer |
| IMGC936 | Phase 1/2 | Advanced Solid Tumor |
| Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off | Phase 1/2 | AML |
| MGD007 + MGA012 | Phase 1/2 | Colorectal Cancer Metastatic |
| MGD010 | Phase 1 | Healthy Subjects |
| Enoblituzumab Schedule 1 | Phase 1 | Melanoma |
| enoblituzumab plus ipilimumab | Phase 1 | Melanoma |
| MGAWN1 | Phase 1 | West Nile Virus |
| MGD020 | Phase 1 | Human Immunodeficiency Virus I Infection |
| teplizumab or placebo | Phase 1 | Type 1 Diabetes Mellitus |
| MGC030 | Phase 1 | Urothelial Cancer |
| monoclonal antibody RAV12 | Phase 1 | Cancer |
| tebotelimab 1 mg | Phase 1 | Advanced Solid Tumors |
| MGC028 | Phase 1 | Advanced Solid Tumors |
| MGD024 | Phase 1 | Leukemia, Acute Myeloid |
| MGC026 Dose Escalation | Phase 1 | Advanced Solid Tumor |
| MGD014 | Phase 1 | HIV-1-infection |
| Flotetuzumab | Phase 1 | Leukemia, Myeloid, Acute |
Latest
- Vobramitamab Duocarmazine moved to Phase 2
- macrogenics filed 8-K
- macrogenics filed 8-K
- macrogenics filed 8-K
- macrogenics filed 8-K
Follow MacroGenics on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.